Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study

References

• World Health Organization. Global health estimates: life expectancy and leading causes of death and disability; 2020. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates. Accessed December 15, 2021.
   Google Scholar
• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858. doi:10.1016/S0140-6736(18)32279-7
   PubMed Web of Science ®Google Scholar
• Afonso ASM, Verhamme KMC, Sturkenboom MC, Brusselle GG. COPD in the general population: prevalence, incidence and survival. Respir Med. 2011;105(12):1872–1884. doi:10.1016/j.rmed.2011.06.012
   PubMed Web of Science ®Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99. doi:10.2147/COPD.S27480
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD Report. Global strategy for the diagnosis, management and prevention of COPD. 2022. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed February 2, 2022.
   Google Scholar
• Trueman D, Woodcock F, Hancock E. Estimating the economic burden of respiratory illness in the UK; 2017. Available from: https://cdn.shopify.com/s/files/1/0221/4446/files/PC-1601_-_Economic_burden_report_FINAL_8cdaba2a-589a-4a49-bd14-f45d66167795.pdf?1309501094450848169&_ga=2.11091697.435115983.1642422068-1593090845.1642422068. Accessed November 24, 2021.
   Google Scholar
• Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118(5):1278–1285. doi:10.1378/chest.118.5.1278
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, Agusti A; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. doi:10.1183/09031936.04.00014304
   PubMed Web of Science ®Google Scholar
• Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245. doi:10.2147/CEOR.S34321
   PubMedGoogle Scholar
• European Respiratory Society. European lung white book; 2013. Available from: https://www.erswhitebook.org/. Accessed January 7, 2022.
   Google Scholar
• Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9(1):65–73. doi:10.2147/COPD.S54417
   PubMed Web of Science ®Google Scholar
• Mapel DW, Schum M, Lydick E, Marton JP. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics. 2010;28(9):733–749. doi:10.2165/11535600-000000000-00000
   PubMed Web of Science ®Google Scholar
• Long H, Xu H, Janssens JP, Guo Y. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials. Respir Res. 2021;22(1):209. doi:10.1186/s12931-021-01794-w
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Visual summary: treatment algorithm; 2019. Available from: https://www.nice.org.uk/guidance/ng115/resources/visual-summary-treatment-algorithm-pdf-6604261741. Accessed June 7, 2021.
   Google Scholar
• Martin A, Shah D, Schroeder M, et al. Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with COPD – cost-effectiveness in the UK. Thorax. 2018;73(Suppl 4):P250.
   Google Scholar
• Anley G, Shah D, Schroeder M, et al. Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus dual bronchodilator therapy (UMEC/VI) in patients with COPD – cost-effectiveness in the UK. Thorax. 2018;73(Suppl 4):P249.
   Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Specialist Pharmacy Service. Budesonide + formoterol + glycopyrronium. Available from: https://www.sps.nhs.uk/medicines/budesonide-formoterol-glycopyrronium/. Accessed December 14, 2021.
   Google Scholar
• European Medicines Agency. Trixeo Aerosphere. Summary of product characteristics; 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/trixeo-aerosphere-epar-product-information_en.pdf. Accessed December 15, 2021.
   Google Scholar
• US Food and Drug Administration. Breztri Aerosphere™: highlights of prescribing information; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212122s000lbl.pdf. Accessed December 15, 2021.
   Google Scholar
• AstraZeneca. Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease; 2019. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-pt010-approved-in-japan-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html. Accessed December 15, 2021.
   Google Scholar
• AstraZeneca. AstraZeneca’s triple-combination therapy approved in China for patients with COPD; 2019. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-triple-combination-therapy-approved-in-china-for-patients-with-copd-23122019.html. Accessed December 15, 2021.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Reimbursement reviews. Budesonide/glycopyrronium/formoterol fumarate; 2021. Available from: https://www.cadth.ca/budesonide-glycopyrronium-formoterol-fumarate. Accessed December 15, 2021.
   Google Scholar
• Australian Government Department of Health Therapeutic Goods Administration. Australian product information. Breztri Aerosphere™ 160/7.2/5 (budesonide/glyopyrronium/formoterol (eformoterol) fumarate dihydrate) pressurised metered dose inhaler; 2021. Available from: http://www.guildlink.com.au/gc/ws/astra/pi.cfm?product=appbrezt10721. Accessed December 15, 2021.
   Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. A Phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol. Respir Med. 2019;158:59–66. doi:10.1016/j.rmed.2019.08.010
   PubMed Web of Science ®Google Scholar
• Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III follow-up study. Int J Chron Obstruct Pulmon Dis. 2009;4:137–148. doi:10.2147/COPD.S5237
   PubMedGoogle Scholar
• Office for National Statistics. National life tables, Scotland: 2016 to 2018; 2019. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesscotlandreferencetables. Accessed June 7, 2021.
   Google Scholar
• Rutten-van Mölken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics. 2009;27(6):465–477. doi:10.2165/00019053-200927060-00003
   PubMed Web of Science ®Google Scholar
• UK National Health Service. Reference cost collection: national schedule of reference costs, 2017/18 - NHS trusts and NHS foundation trusts; 2019. Available from: https://webarchive.nationalarchives.gov.uk/ukgwa/20200501111106/https://improvement.nhs.uk/resources/reference-costs/. Accessed June 7, 2021.
   Google Scholar
• Information Services Division Scotland. National statistics release - outpatients - specialty costs and activity - nurse led clinics, by specialty, by hospital; 2019. Available from: https://www.isdscotland.org/health-topics/finance/costs/Detailed-Tables/Speciality-Costs/Outpatients.asp. Accessed December 12, 2019.
   Google Scholar
• Personal Social Services Research Unit. Unit costs of health and social care 2015; 2015. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2015/. Accessed June 7, 2021.
   Google Scholar
• Personal Social Services Research Unit. Unit costs of health and social care 2018; 2018. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2018/. Accessed June 7, 2021.
   Google Scholar
• National Institute for Health and Care Excellence. British national formulary. Available from: https://bnf.nice.org.uk/. Accesssed June 7, 2021.
   Google Scholar
• Information Services Division Scotland. National statistics release - acute medical - specialty costs and activity - inpatients in all specialties (exc long stay), by hospital; 2019. Available from: https://www.isdscotland.org/Health-Topics/Finance/Costs/Detailed-Tables/Speciality-Costs/Acute-Medical.asp. Accessed December 12, 2019.
   Google Scholar
• Personal Social Services Research Unit. Unit costs of health and social care 2020; 2020. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020/. Accessed June 7, 2021.
   Google Scholar
• Briggs AH, Baker T, Risebrough NA, et al. Development of the Galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Making. 2017;37(4):469–480. doi:10.1177/0272989X16653118
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. The guidelines manual. Process and methods [PMG6]. 7 Assessing cost effectiveness; 2012. Available from: https://www.nice.org.uk/process/pmg6/chapter/assessing-cost-effectiveness. Accessed June 7, 2021.
   Google Scholar
• Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7(1):480. doi:10.1183/23120541.00480-2020
   PubMedGoogle Scholar
• Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017;12:997–1008. doi:10.2147/COPD.S124420
   PubMed Web of Science ®Google Scholar
• van Boven JF, Kocks JW, Postma MJ. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis. 2016;11:2191–2201. doi:10.2147/COPD.S114738
   PubMed Web of Science ®Google Scholar
• Negro RD, Eandi M, Pradelli L, Iannazzo S. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(2):169–176.
   PubMedGoogle Scholar
• Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:183–199. doi:10.2147/COPD.S29820
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Roflumilast for treating chronic obstructive pulmonary disease. Technology appraisal guidance [ID984]; 2016. Available from: https://www.nice.org.uk/guidance/ta461. Accessed June 7, 2021.
   Google Scholar
• Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, Al MJ, Feenstra TL. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011;14(8):1039–1047. doi:10.1016/j.jval.2011.06.008
   PubMed Web of Science ®Google Scholar
• Huang WC, Chen CY, Liao WC, et al. A real world study to assess the effectiveness of switching to once daily closed triple therapy from mono/dual combination or open triple therapy in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1555–1568. doi:10.2147/COPD.S308911
   PubMed Web of Science ®Google Scholar
• de Nigris E, Holmgren U, Treharne C, Brighton N, Walker A, Haughney J. Cost minimization analysis of fixed-dose triple therapy with budesonide/glycopyrronium/formoterol fumarate versus open triple therapy for moderate-to-very severe COPD in the United Kingdom. Value Health. 2022;25(Suppl 1):POSA68.
   Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.040527
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-201518
   PubMed Web of Science ®Google Scholar
• DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 Update. Ann Intern Med. 2022;175(9):1298–1304. doi:10.7326/M22-1460
   PubMed Web of Science ®Google Scholar